It should be noted that in various experimental models SFRP3 acts as an antagonist or agonist of the Wnt signalling pathway, causing an increase in the concentration of this protein in states of tumour progression and metastasis (Pećina-Šlaus et al. 2016). The gene discussed is FRZB; the disease is neoplasm.